Philip Krape is the new senior director at business development, and Robert Small is the new senior director for biostatistics and data management at AtheroGenics.
Krape joins the biopharmaceutical firm from aaiPharma, where he served as senior director of business development. Krape also worked for 26 years at DuPont de Nemours & Company.
Krape will be tasked with licensing and pre-commercialization actions for the launch of AthernoGenics’ arteriosclerosis drug candidate known as AGI-1067.
Small’s most recent position as as vice president of data mining technologies at GlaxoSmithKline. He also worked at Pfizer.